Drug Trial Radar · NCT07437950
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Sep 25, 2026
Primary completion
Sep 22, 2034
Study completion Sep 22, 2034
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Shorter duration venetoclax may be as effective as standard duration venetoclax when given with ASTX727 for the treatment of newly diagnosed AML.
Conditions
- Acute Myeloid Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Decitabine and CedazuridineDrug
Given PO
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal residual disease (MRD) negative complete remission (CR)Time frame: At 180 days
Locations
83 sites in 2 countries. Site status is shown where the registry gives one.
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Illinois CancerCare-Bloomington
Bloomington, Illinois · Recruiting
Illinois CancerCare-Canton
Canton, Illinois · Recruiting
Illinois CancerCare-Carthage
Carthage, Illinois · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Illinois CancerCare-Eureka
Eureka, Illinois · Recruiting
Illinois CancerCare-Galesburg
Galesburg, Illinois · Recruiting
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois · Recruiting
Illinois CancerCare-Macomb
Macomb, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois · Recruiting
Cancer Care Center of O'Fallon
O'Fallon, Illinois · Recruiting
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois · Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois · Recruiting
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois · Recruiting
Illinois CancerCare-Pekin
Pekin, Illinois · Recruiting
Illinois CancerCare-Peoria
Peoria, Illinois · Recruiting
Illinois CancerCare-Peru
Peru, Illinois · Recruiting
Illinois CancerCare-Princeton
Princeton, Illinois · Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
Springfield Memorial Hospital
Springfield, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
Illinois CancerCare - Washington
Washington, Illinois · Recruiting
UChicago Medicine Northwest Indiana
Crown Point, Indiana · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana · Recruiting
Our Lady of the Lake Physician Group
Baton Rouge, Louisiana · Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan · Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan · Recruiting
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan · Recruiting
OSF Saint Francis Hospital and Medical Group
Escanaba, Michigan · Recruiting
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan · Recruiting
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.